Research programme: gene therapies - Generation Bio
Latest Information Update: 28 Nov 2024
At a glance
- Originator Generation Bio
- Class Antihaemorrhagics; Eye disorder therapies; Gene therapies; Hepatoprotectants
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Eye disorders
- No development reported Gaucher's disease; Haemophilia A; Hepatolenticular degeneration; Inborn genetic disorders; Liver disorders; Phenylketonuria; Stargardt disease; Wet age-related macular degeneration
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Haemophilia-A in USA (Parenteral)
- 28 Nov 2024 No recent reports of development identified for preclinical development in Phenylketonuria in USA (Parenteral)
- 28 Nov 2024 No recent reports of development identified for research development in Gaucher's-disease in USA (Parenteral)